Du är här


co.don AG : Successful capital increase

co.don AG / co.don AG : Successful capital increase. Processed and transmitted
by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
+ all available shares successfully sold

+ capital increase oversubscribed by 72%

Teltow, 15.05.2014
- The biopharma company co.don® AG, listed on the General Standard of the
Frankfurt Stock Exchange, (ISIN: DE000A1K0227/ WKN A1K022) has successfully
completed a capital increase for subscription in cash from authorised

By making use of the authorised capital created by the shareholders' meeting
on 7 August 2013 the share capital was increased by cash subscriptions from
€11,108,584 by €2,613,784 to €13,722,368 for the issue of 2,613,784 new
bearer shares at a price of €1.90 per share. Shareholders were offered the
new shares by way of an indirect rights issue. Shareholders were also
entitled to place orders for additional new shares at the issue price when
exercising their subscription rights. The subscription period began on 28
April 2014 and ended on 13 May 2014.

Shares not purchased by shareholders during this period were offered for sale
to third parties on the same terms as part of a private placement.

In total, subscription requests were received for 4,503,978 shares. This
oversubscription meant that not enough new shares were available to satisfy
all the requests from existing shareholders and the private placement, so
both groups of investors were treated equally.

"I am very pleased by this vote of confidence from both our existing and our
new investors, to whom I would like to extend a particularly warm welcome.
The oversubscription shows the strong level of interest in our company", said
Dr. Andreas Baltrusch, CEO of co.don® AG.

The proceeds of the capital increase are mainly to be used to carry out
further clinical trials to obtain central EU-wide approval for the cell-based
pharmaceutical productchondrosphere®
. In addition, co.don® AG has a method of cultivating autologous disc cells
for the regenerative treatment of herniated vertebral discs known as co.don
chondrotransplant® DISC. The issue proceeds are also intended to enable
preliminary work relevant to its approval process to be carried out.

biw Bank für Investments und Wertpapiere AG, Willich, acted as the
subscription agent, SCHNIGGE Wertpapierhandelsbank AG was responsible for the
placement of the shares not purchased by existing shareholders.

About co.don® AG: The biopharmaceutical companyis one of the leading
specialists worldwide in cell cultivation for the
regenerative treatment of articular cartilage defects and spinal disc defects
.In many cases the use of the company's patented pharmaceutical product can
avert the need for joint and spinal disc replacement surgery. Orthopaedic,
accident and neuro-surgeons are increasingly applying these regenerative
treatment methods. co.don® AG is listed on the Frankfurt Stock Exchange
(ISIN: DE000A1K0227). The company's Executive Board consists of Dr. Andreas
Baltrusch (CEO, CFO) and Ms Vilma Methner (COO, CSO).

Further information about co.don AG can be found at:



Matthias Meißner, M.A.

Investor relations



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: co.don AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.